Fixed-dose combination
Halobetasol propionate and Tazarotene is a fixed-dose combination of a corticosteroid and a retinoid indicated for the topical treatment of plaque psoriasis in adults. It is available as lotion for topical use. MedsAcross supplies Halobetasol propionate and Tazarotene for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
DUOBRII ® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045% is indicated for the topical treatment of plaque psoriasis in adults. DUOBRII Lotion is a combination of halobetasol propionate and tazarotene indicated for the topical treatment of plaque psoriasis in adults.
Source: US FDA prescribing information
Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation, however, the precise mechanism of action in plaque psoriasis is unknown. Tazarotene is a retinoid prodrug which is converted to its active form, tazarotenic acid, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ and RARγ, but shows relative selectivity for RARβ, and RARγ and may modify gene expression. The clinical significance of these findings for the treatment of plaque psoriasis is unknown.
Source: US FDA prescribing information
Apply a thin layer of DUOBRII Lotion once daily to cover only affected areas and rub in gently. If a bath or shower is taken prior to application, the skin should be dry before applying the lotion. The total dosage should not exceed approximately 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Do not use with occlusive dressings unless directed by a physician. Discontinue treatment when control is achieved. Avoid application of DUOBRII Lotion on the face, groin, or in the axillae. DUOBRII Lotion is not for oral, ophthalmic, or intravaginal use. • Apply a thin layer of DUOBRII Lotion to the affected areas once daily. • Not for oral, ophthalmic, or intravaginal use.
Source: US FDA prescribing information
DUOBRII Lotion is contraindicated in pregnancy Pregnancy DUOBRII Lotion is contraindicated in pregnancy.
Source: US FDA prescribing information
• Embryofetal risk: DUOBRII Lotion contains tazarotene, which is a teratogenic substance. In females of reproductive potential, obtain a negative pregnancy test within 2 weeks prior to initiating treatment and advise patients to use an effective method of contraception during treatment. • Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, with the potential for glucocorticosteroid insufficiency during or after treatment. • Systemic effects of topical corticosteroids may also include Cushing’s syndrome, hyperglycemia, and glucosuria. • Systemic absorption may require evaluation for HPA axis suppression. • Use of potent corticosteroids on large areas, for prolonged durations, under occlusive dressings, or on an altered skin barrier may increase systemic exposure.
Source: US FDA prescribing information
• The most common adverse reactions are contact dermatitis (7%), application site pain (3%), folliculitis (2%), skin atrophy (2%), and excoriation (2%).
Source: US FDA prescribing information
Conditions Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F). Protect from freezing.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Halobetasol propionate and Tazarotene, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Duobrii 0.1 mg/0.45 mg per g lotionTopical | Halobetasol propionate and Tazarotene | Bausch Health | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 25 April 2019 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Halobetasol propionate and Tazarotene and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Halobetasol propionate and Tazarotene, including Duobrii.
Yes. The US FDA first approved Halobetasol propionate and Tazarotene on 25 April 2019, according to Drugs@FDA.
No listed presentation of Halobetasol propionate and Tazarotene is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.